DonaldCharlesGoffMD

Psychosomatic Medicine

Marvin Stern Professor of Psychiatry Vice Chair for Research, Department of Psychiatry, NYU School of Medicine Director, Nathan Kline Institute for Psychiatric Research

Join to view full profile

Dr. Goff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goff's full profile

Already have an account?

Office
1 Park Ave
Rm 8-212
New York, NY 10016
Phone+1 646-754-4843

Fax+1 646-754-4781

Education & Training

Tufts Medical CenterFellowship, Psychosomatic Medicine, 1984 - 1985
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1984
Cedars-Sinai Medical CenterInternship, Internal Medicine, 1980 - 1981
David Geffen School of Medicine at UCLAClass of 1980

Certifications & Licensure

CA State Medical License 1985 - Present
NY State Medical License 2011 - 2025
MA State Medical License 1982 - 2013
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2013-2014
America's Top Doctors Castle Connolly, 2008-2014
Boston Magazine Castle Connolly, 2008-2011
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Trial of D-Cycloserine in Schizophrenia Start of enrollment: 1996 Aug 01
Completed
Phase 3
Glycine and D-Cycloserine in Schizophrenia Start of enrollment: 1998 Mar 01
Withdrawn
Phase 3
Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia Start of enrollment: 2002 Feb 01
Completed
Phase 2, Phase 3
Folate Supplementation in Schizophrenia Start of enrollment: 2003 Dec 01
Completed
Phase 4
Risperidone Augmentation in Patients With Schizophrenia Start of enrollment: 2003 Feb 01
Completed
Phase 4
The Partners Genetics Collaborative Study of Schizophrenia Start of enrollment: 2001 Mar 01
Completed
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms Start of enrollment: 2006 Jan 01
Completed
Phase 3
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia Start of enrollment: 2004 Jul 01
Completed
Phase 4
A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia Start of enrollment: 2006 Feb 01
Completed
Phase 4
A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia Start of enrollment: 2003 Sep 01
Completed
Phase 4
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia Start of enrollment: 2007 Dec 01
Completed
Phase 4
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia Start of enrollment: 2006 Sep 01
Completed
Phase 4
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia Start of enrollment: 2009 Aug 01
Completed
Not Applicable
Once Weekly D-cycloserine for Schizophrenia Start of enrollment: 2009 Jul 01
Withdrawn
Phase 4
DECIFER: Depression and Citalopram In First Episode Recovery Start of enrollment: 2010 Jan 01
Completed
Phase 4
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Start of enrollment: 2014 Feb 01
Completed
Phase 4
Biomarkers in First Episode Schizophrenia Start of enrollment: 2012 Jul 01
Completed
Levetiracetam in Early Psychosis Start of enrollment: 2017 Aug 18
Completed
Phase 2
Hippocampal Memory Circuits in Delusions Start of enrollment: 2019 Jul 13
Completed
Join now to see all

Publications & Presentations

PubMed

Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.
Katlyn Nemani, Livia De Picker, Faith Dickerson, Marion Leboyer, Michele Santacatterina
Brain, Behavior, & Immunity - Health. 2024-07-01
1 citations
Microstructural and Microvascular Alterations in Psychotic Spectrum Disorders: A Three-Compartment Intravoxel Incoherent Imaging and Free Water Model.
Faye McKenna, Pradeep Kumar Gupta, Yu Veronica Sui, Hilary Bertisch, Oded Gonen
Schizophrenia Bulletin. 2023-11-29
2 citations
Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
Donald C Goff, Joshua Roffman, Daphne J Holt
The American Journal of Psychiatry. 2023-11-01

Journal Articles

Association of Psychiatric Disorders with Mortality Among Patients with COVID-19
Mark Olfson, Donald C Goff, JAMA Psychiatry
The Pharmacologic Treatment of Schizophrenia—2021
Donald Goff, MD, JAMA
Psychiatry and COVID-19
Roy Perlis, Donald Goff, JAMA

Press Mentions

Atypical Antipsychotics Linked to Lower Odds of COVIDMay 6th, 2022
COVID-19 Greatly Increases Mortality Risk for Schizophrenia Patients, Research ShowsFebruary 26th, 2021
‘Alarming Finding’ in Schizophrenia Patients with COVID-19February 2nd, 2021
Join now to see all

Grant Support

Citalopram In First Episode SchizophreniaNational Institute Of Mental Health2012
Citalopram In First Episode SchizophreniaNational Institute Of Mental Health2009–2011
New Treatment And Mechanisms In SchizophreniaNational Institute Of Mental Health2001–2011
Folate In SchizophreniaNational Institute Of Mental Health2007–2010
Relapse Prevention: Long-Acting Atypical AntipsychoticsNational Institute Of Mental Health2006–2010
NMDA Receptor Function In SchizophreniaNational Institute Of Mental Health2000–2002
A Trial Of D-Cycloserine In SchizophreniaNational Center For Research Resources1997–2002
Glycine And D-Cycloserine In SchizophreniaNational Institute Of Mental Health1998–2000
Trial Of D-Cycloserine In SchizophreniaNational Institute Of Mental Health1996–1998
Excitatory Amino Acids In SchizophreniaNational Center For Research Resources1997
Lactate/Pyruvate Ratio In Cerebrospinal Fluid--Tardive DyskinesiaNational Center For Research Resources1996
Faculty Scholar Award In SchizophreniaNational Institute Of Mental Health1988–1990